Oliver Lagore Vanvalin Investment Group Raises Position in Danaher Co. (NYSE:DHR)

Oliver Lagore Vanvalin Investment Group lifted its stake in shares of Danaher Co. (NYSE:DHR) by 12.3% during the second quarter, Holdings Channel reports. The fund owned 4,098 shares of the conglomerate’s stock after acquiring an additional 448 shares during the period. Oliver Lagore Vanvalin Investment Group’s holdings in Danaher were worth $1,024,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of DHR. Tsfg LLC raised its position in Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new position in Danaher in the second quarter worth approximately $25,000. nVerses Capital LLC acquired a new position in Danaher during the 2nd quarter worth approximately $25,000. Redmont Wealth Advisors LLC acquired a new stake in shares of Danaher in the 1st quarter valued at $30,000. Finally, Richardson Financial Services Inc. purchased a new stake in shares of Danaher during the 4th quarter worth $42,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Jefferies Financial Group initiated coverage on Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price target on the stock. Leerink Partners increased their price target on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Evercore ISI decreased their price objective on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Bank of America lifted their target price on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Finally, Wells Fargo & Company assumed coverage on Danaher in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price for the company. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average price target of $278.94.

Danaher Trading Down 0.5 %

Shares of DHR stock opened at $275.47 on Friday. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The business’s fifty day moving average price is $270.23 and its 200 day moving average price is $257.84. The firm has a market capitalization of $204.04 billion, a PE ratio of 46.69, a P/E/G ratio of 4.55 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same quarter last year, the business earned $2.05 earnings per share. As a group, sell-side analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.39%. Danaher’s dividend payout ratio is presently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.